Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results From INTRIGUE Phase 3 Clinical Study In Second-Line GIST Patients At The 2024 American Society Of Clinical Oncology Gastrointestinal Cancers Symposium
Portfolio Pulse from Benzinga Newsdesk
Deciphera Pharmaceuticals (NASDAQ:DCPH) presented long-term results from the INTRIGUE Phase 3 study of QINLOCK in second-line GIST patients at the ASCO Gastrointestinal Cancers Symposium. The study compared QINLOCK to sunitinib, showing a median overall survival of 35.5 months for QINLOCK versus 31.5 months for sunitinib. QINLOCK demonstrated a favorable safety profile with fewer Grade 3/4 TEAEs and lower treatment discontinuation rates. The results support QINLOCK as a preferred second-line regimen for advanced GIST patients intolerant to sunitinib, as per NCCN Guidelines. An exploratory analysis showed clinical benefit for QINLOCK in patients with specific KIT mutations, leading to the INSIGHT Phase 3 study enrollment.
January 18, 2024 | 4:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Deciphera Pharmaceuticals' QINLOCK shows improved safety and comparable efficacy to sunitinib in long-term study results, potentially reinforcing its position as a preferred second-line treatment for GIST.
The positive long-term results from the INTRIGUE study are likely to reinforce investor confidence in QINLOCK and Deciphera Pharmaceuticals. The favorable safety profile and inclusion in the NCCN Guidelines as a preferred regimen could lead to increased adoption and sales, positively impacting the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100